Vertex Pharmaceuticals (VRTX) Non-Current Deferred Tax Liability (2009 - 2018)

Vertex Pharmaceuticals' Non-Current Deferred Tax Liability history runs 10 years deep, the most recent figure standing at $9.4 million for Q3 2018.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 11.87% year-over-year to $9.4 million in Q3 2018; TTM through Sep 2018 was $9.4 million, a 11.87% decrease from a year earlier, with the FY2017 full-year figure at $6.3 million, down 95.27% from the prior year.
• Non-Current Deferred Tax Liability climbed to $9.4 million in Q3 2018 per VRTX's latest filing, from $9.3 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $136.6 million in Q2 2017 and bottomed at $6.3 million in Q4 2017.
• The 5-year median for Non-Current Deferred Tax Liability is $111.2 million (2015), against an average of $74.8 million.
• Across the five-year window, Non-Current Deferred Tax Liability soared 643.78% in 2016 and sank 95.27% in 2017, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $15.0 million in 2014, then surged by 631.75% to $110.1 million in 2015, then climbed by 21.78% to $134.1 million in 2016, then tumbled by 95.27% to $6.3 million in 2017, then jumped by 48.46% to $9.4 million in 2018.
• Per Business Quant, the three latest VRTX Non-Current Deferred Tax Liability figures stand at $9.4 million (Q3 2018), $9.3 million (Q2 2018), and $9.6 million (Q1 2018).